Founded in 2006, Cyagen is a global provider of genetically modified rodent models and advanced CRO solutions for biomedical research and drug development. With more than 900 employees and multiple research facilities covering 40,000 m², we serve researchers in more than 100 countries and support over 13,000 peer-reviewed publications – including in Cell, Nature, and Science.

Headquartered in Santa Clara, California, Cyagen also operates subsidiaries in Japan and China, along with major R&D and production centers in Guangzhou, Suzhou, and Gu'an (China). Leveraging its robust foundation in cell and animal model generation alongside powerful AI-driven discovery platforms, Cyagen offers scalable, reliable, and expert-backed one-stop solutions for accelerating both basic research and preclinical drug development.

To further advance translational research, Cyagen has developed several proprietary platforms:

- HUGO-GT™ is a portfolio of genomic sequence humanized mouse models for translational research and drug discovery.

- RDDC (Rare Disease Data Center) integrates genetic and disease databases, animal model resources with AI tools to benefit global biomedical research community.

- HUGO-Ab™ provides next-generation fully human antibody mouse platforms for efficient therapeutic antibody discovery.

- Abseek™ is our AI-powered platform for antibody screening, engineering, and design – streamlining antibody discovery from ideas to IND.

These innovations underscore our commitment to making research more efficient, accurate, and impactful.